These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29348462)

  • 21. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
    Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
    Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
    Tanaka N; Patel AA; Tang L; Silver NL; Lindemann A; Takahashi H; Jaksik R; Rao X; Kalu NN; Chen TC; Wang J; Frederick MJ; Johnson F; Gleber-Netto FO; Fu S; Kimmel M; Wang J; Hittelman WN; Pickering CR; Myers JN; Osman AA
    Clin Cancer Res; 2017 Nov; 23(21):6541-6554. PubMed ID: 28790110
    [No Abstract]   [Full Text] [Related]  

  • 23. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
    Brown MS; Diallo OT; Hu M; Ehsanian R; Yang X; Arun P; Lu H; Korman V; Unger G; Ahmed K; Van Waes C; Chen Z
    Clin Cancer Res; 2010 Apr; 16(8):2295-307. PubMed ID: 20371694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
    Tessoulin B; Descamps G; Moreau P; Maïga S; Lodé L; Godon C; Marionneau-Lambot S; Oullier T; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Blood; 2014 Sep; 124(10):1626-36. PubMed ID: 25006124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
    Liu DS; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
    Gut; 2015 Oct; 64(10):1506-16. PubMed ID: 26187504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.
    Liu J; Uematsu H; Tsuchida N; Ikeda MA
    Mol Cancer; 2011 Jul; 10():95. PubMed ID: 21801448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than
    Fujihara KM; Corrales Benitez M; Cabalag CS; Zhang BZ; Ko HS; Liu DS; Simpson KJ; Haupt Y; Lipton L; Haupt S; Phillips WA; Clemons NJ
    Mol Cancer Ther; 2021 Oct; 20(10):1858-1867. PubMed ID: 34315763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.
    Cabelguenne A; Loriot MA; Stucker I; Blons H; Koum-Besson E; Brasnu D; Beaune P; Laccourreye O; Laurent-Puig P; De Waziers I
    Int J Cancer; 2001 Sep; 93(5):725-30. PubMed ID: 11477586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
    Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
    Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
    Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
    Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.
    Saleh AD; Cheng H; Martin SE; Si H; Ormanoglu P; Carlson S; Clavijo PE; Yang X; Das R; Cornelius S; Couper J; Chepeha D; Danilova L; Harris TM; Prystowsky MB; Childs GJ; Smith RV; Robertson AG; Jones SJM; Cherniack AD; Kim SS; Rait A; Pirollo KF; Chang EH; Chen Z; Van Waes C
    Clin Cancer Res; 2019 May; 25(9):2860-2873. PubMed ID: 30723145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
    Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Association of the expression of p53 and p16INK4A with the clinical and morphological characteristicsof patients with head and neck squamous cell cancer].
    Stukan AI; Chukhray OY; Porkhanov VA; Bodnya VN
    Arkh Patol; 2019; 81(3):12-18. PubMed ID: 31317926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.
    Basak D; Punganuru SR; Srivenugopal KS
    Int J Oncol; 2016 Apr; 48(4):1426-36. PubMed ID: 26848023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
    Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
    Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.